Last reviewed · How we verify
NCT06747325
Clinical Trial of Fei Re Qing Granules in the Treatment of Elderly Community-Acquired Pneumonia
NA trial testing Fei Re Qing Granules in Community-Acquired Pneumonia (CAP) in 120 participants. Not yet recruiting.
1 May 2025
Quick facts
| Lead sponsor | Henan University of Traditional Chinese Medicine |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 120 |
| Start date | 1 January 2025 |
| Primary completion | 1 May 2025 |
| Estimated completion | 1 June 2025 |
Drugs / interventions tested
- Fei Re Qing Granules — full drug profile →
- Routine standard treatments
- Placebo granules
Conditions studied
- Community-Acquired Pneumonia (CAP) — all drugs for Community-Acquired Pneumonia (CAP) →
Sponsor
Henan University of Traditional Chinese Medicine
Who can join
Adults 65 to 80, any sex, with Community-Acquired Pneumonia (CAP). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to evaluate the clinical efficacy of traditional Chinese medicine formula granules (Fei Re Qing Granules) in the treatment of elderly community-acquired pneumonia, establish a treatment protocol, and obtain high-level clinical evidence.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06747325
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Fei Re Qing Granules
Trials testing the same drug.
- NCT07206745 — A Study on Integrated Chinese and Western Medicine for Severe Pneumonia Caused by Multidrug-Resistant Gram-Negative Bact · NA · not yet recruiting
Other recruiting trials for Community-Acquired Pneumonia (CAP)
Currently open trials in the same condition.
- NCT07359287 — Impact of a Multimodal Intervention on Antibiotic Prescribing for Respiratory Infections in Primary Care · NA · recruiting
- NCT06782282 — A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and Older · active not recruiting
Other Henan University of Traditional Chinese Medicine trials
Trials by the same sponsor.
- NCT07352488 — Modified Shenling Baizhu Powder for Allergic Asthma With Spleen Deficiency and Dampness Accumulation Syndrome · NA · not yet recruiting
- NCT07206745 — A Study on Integrated Chinese and Western Medicine for Severe Pneumonia Caused by Multidrug-Resistant Gram-Negative Bact · NA · not yet recruiting
- NCT07178392 — Disease-syndrome Characteristics of IPF · not yet recruiting
- NCT07162870 — Idiopathic Pulmonary Fibrosis Cohort of TCM · not yet recruiting
- NCT06914713 — Jin-shui Huan-xian Formula for Retarding the Decline of Pulmonary Function in IPF · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06747325 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Henan University of Traditional Chinese Medicine
- Last refreshed: 24 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06747325.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing